P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients
The objective of the present study was to evaluate the effects of an imidazoline agonist, Moxonidine, on sympathetic nervous activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. Forty obese hypertensive, non diabetic patients were randomized to receive...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension 2002-04, Vol.15 (S3), p.51A-52A |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 52A |
|---|---|
| container_issue | S3 |
| container_start_page | 51A |
| container_title | American journal of hypertension |
| container_volume | 15 |
| creator | Sanjuliani, A.F. Genelhu-Fagundes, V. Barroso, S.G. Duarte, A.V.B. Rodrigues, M.L.G. Castro, R.S.P. Lau, C.S.C. Francischetti, E.A. |
| description | The objective of the present study was to evaluate the effects of an imidazoline agonist, Moxonidine, on sympathetic nervous activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. Forty obese hypertensive, non diabetic patients were randomized to receive during 6 months Moxonidine (M), 0.2mg/day adjusted to 0.4 mg/day [3 males, 16 females, age = 50.3±1.9 yrs, BMI=35.4±1.7, mean blood pressure (MBP)=128±1.3 mmHg] or Amlodipine (AM) 5mg adjusted to 10 mg/day (4 males, 17 females, age 46.9±2.1 yrs, BMI = 35.9±1.4; MBP 122.7±1.7 mmHg). We evaluated the sympathetic activity by determination of arterial and venous cathecolamines (the last at supine and post-exercise othostatic position), serum insulin (fasting and 2h post oral glucose challenge), fasting leptin, lipid profile and anthropometrical variables. All these variables were measured before (V1), after 3 months (V2) and 6 months (V3) of treatment with both agents. Analysis of variance was used to evaluate the effects of both treatments. The following are results obtained at V1 and V3: A significant reduction on levels of blood pressure was achieved equally in both groups (MBP: 121.8±1.3 vs 107.1±2.0 mmHg for M and 158.1±3.1 vs 134.2±1.7 mmHg for A; all p |
| doi_str_mv | 10.1016/S0895-7061(02)02403-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1026584038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2712863881</sourcerecordid><originalsourceid>FETCH-LOGICAL-i668-ca6ea6eebcc0519017fe725ec8484ae08c301abe02236a6f9bae6acac61faf483</originalsourceid><addsrcrecordid>eNo9kF9LwzAUxYMoOKcfQQj4omA1Sdu09U3GdMLwDxsivpTb7IZlrslssrHil7djIhy4nMuPc-AQcs7ZDWdc3k5YXqRRxiS_ZOKKiYTFkTggPV4kPMqESA9J7x85JifeLxhjiZS8R35eo1Tc0aHWqIKnTtPabZ01M2OROkt9W68gzDEYRUEFszGhvaZgZ7TGAJVb7v6dm2PtZq2FuvMbaAxUS_TUWOoq9Ejn7QqbgNabDdIu0KAN_pQcaVh6PPu7fTJ9GE4Ho2j88vg0uB9HRso8UiCxE1ZKsZQXjGcaM5GiypM8AWS5ihmHCpkQsQSpiwpQggIluQad5HGfXOxjV437XqMP5cKtG9s1lpwJmebdXjsq2lPGB9yWq8bU0LQlNF-lzOIsLUcfn6WYDLod35_Lt_gXmrdxzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026584038</pqid></control><display><type>article</type><title>P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients</title><source>Alma/SFX Local Collection</source><source>Oxford Journals</source><creator>Sanjuliani, A.F. ; Genelhu-Fagundes, V. ; Barroso, S.G. ; Duarte, A.V.B. ; Rodrigues, M.L.G. ; Castro, R.S.P. ; Lau, C.S.C. ; Francischetti, E.A.</creator><creatorcontrib>Sanjuliani, A.F. ; Genelhu-Fagundes, V. ; Barroso, S.G. ; Duarte, A.V.B. ; Rodrigues, M.L.G. ; Castro, R.S.P. ; Lau, C.S.C. ; Francischetti, E.A.</creatorcontrib><description><![CDATA[The objective of the present study was to evaluate the effects of an imidazoline agonist, Moxonidine, on sympathetic nervous activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. Forty obese hypertensive, non diabetic patients were randomized to receive during 6 months Moxonidine (M), 0.2mg/day adjusted to 0.4 mg/day [3 males, 16 females, age = 50.3±1.9 yrs, BMI=35.4±1.7, mean blood pressure (MBP)=128±1.3 mmHg] or Amlodipine (AM) 5mg adjusted to 10 mg/day (4 males, 17 females, age 46.9±2.1 yrs, BMI = 35.9±1.4; MBP 122.7±1.7 mmHg). We evaluated the sympathetic activity by determination of arterial and venous cathecolamines (the last at supine and post-exercise othostatic position), serum insulin (fasting and 2h post oral glucose challenge), fasting leptin, lipid profile and anthropometrical variables. All these variables were measured before (V1), after 3 months (V2) and 6 months (V3) of treatment with both agents. Analysis of variance was used to evaluate the effects of both treatments. The following are results obtained at V1 and V3: A significant reduction on levels of blood pressure was achieved equally in both groups (MBP: 121.8±1.3 vs 107.1±2.0 mmHg for M and 158.1±3.1 vs 134.2±1.7 mmHg for A; all p<0.0001). Arterial nor-epinephrine (art NE) concentrations decreased significantly on M group (233.6±13.2 vs 194.3± 14.4 pg/ml, p<0.05) but not on AM group (195.5±15.2 vs 188.7±16.3, p=ns). Leptin concentrations also decreased significantly in M group (25.1±3.1vs 22.6±2.9 ng/ml, p=0.03) and increased in AM group (33.4±3.6 vs 36.6±7.9 ng/ml). Although no significant differences were registered on fasting serum insulin, we observed a significant decrease on 120 min. of insulin concentrations in M group (139.5±33.0 vs 71.2±14.5 μU/ml, p<0.05 ) but not in AM group (94.4±19.3 vs 88.5±11.5μU/ml, p=ns). The changes on art NE were directly associated to changes on 2h insulin (r=0.53, p<0.04) serum triglycerides (r=0.63, p<0.03) only in M group. The changes on serum leptin were also directly associated to 2h insulin (r=0.58, p<0.04) in M group. The beneficial effect achieved by Moxonidine goes beyond blood pressure control as result of a better metabolic profile associated with lower sympathetic activity.]]></description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(02)02403-2</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Insulin Resistance ; Moxonidine ; Sympathetic Activity</subject><ispartof>American journal of hypertension, 2002-04, Vol.15 (S3), p.51A-52A</ispartof><rights>Copyright Nature Publishing Group Apr 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Genelhu-Fagundes, V.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Duarte, A.V.B.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Castro, R.S.P.</creatorcontrib><creatorcontrib>Lau, C.S.C.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><title>P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description><![CDATA[The objective of the present study was to evaluate the effects of an imidazoline agonist, Moxonidine, on sympathetic nervous activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. Forty obese hypertensive, non diabetic patients were randomized to receive during 6 months Moxonidine (M), 0.2mg/day adjusted to 0.4 mg/day [3 males, 16 females, age = 50.3±1.9 yrs, BMI=35.4±1.7, mean blood pressure (MBP)=128±1.3 mmHg] or Amlodipine (AM) 5mg adjusted to 10 mg/day (4 males, 17 females, age 46.9±2.1 yrs, BMI = 35.9±1.4; MBP 122.7±1.7 mmHg). We evaluated the sympathetic activity by determination of arterial and venous cathecolamines (the last at supine and post-exercise othostatic position), serum insulin (fasting and 2h post oral glucose challenge), fasting leptin, lipid profile and anthropometrical variables. All these variables were measured before (V1), after 3 months (V2) and 6 months (V3) of treatment with both agents. Analysis of variance was used to evaluate the effects of both treatments. The following are results obtained at V1 and V3: A significant reduction on levels of blood pressure was achieved equally in both groups (MBP: 121.8±1.3 vs 107.1±2.0 mmHg for M and 158.1±3.1 vs 134.2±1.7 mmHg for A; all p<0.0001). Arterial nor-epinephrine (art NE) concentrations decreased significantly on M group (233.6±13.2 vs 194.3± 14.4 pg/ml, p<0.05) but not on AM group (195.5±15.2 vs 188.7±16.3, p=ns). Leptin concentrations also decreased significantly in M group (25.1±3.1vs 22.6±2.9 ng/ml, p=0.03) and increased in AM group (33.4±3.6 vs 36.6±7.9 ng/ml). Although no significant differences were registered on fasting serum insulin, we observed a significant decrease on 120 min. of insulin concentrations in M group (139.5±33.0 vs 71.2±14.5 μU/ml, p<0.05 ) but not in AM group (94.4±19.3 vs 88.5±11.5μU/ml, p=ns). The changes on art NE were directly associated to changes on 2h insulin (r=0.53, p<0.04) serum triglycerides (r=0.63, p<0.03) only in M group. The changes on serum leptin were also directly associated to 2h insulin (r=0.58, p<0.04) in M group. The beneficial effect achieved by Moxonidine goes beyond blood pressure control as result of a better metabolic profile associated with lower sympathetic activity.]]></description><subject>Insulin Resistance</subject><subject>Moxonidine</subject><subject>Sympathetic Activity</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo9kF9LwzAUxYMoOKcfQQj4omA1Sdu09U3GdMLwDxsivpTb7IZlrslssrHil7djIhy4nMuPc-AQcs7ZDWdc3k5YXqRRxiS_ZOKKiYTFkTggPV4kPMqESA9J7x85JifeLxhjiZS8R35eo1Tc0aHWqIKnTtPabZ01M2OROkt9W68gzDEYRUEFszGhvaZgZ7TGAJVb7v6dm2PtZq2FuvMbaAxUS_TUWOoq9Ejn7QqbgNabDdIu0KAN_pQcaVh6PPu7fTJ9GE4Ho2j88vg0uB9HRso8UiCxE1ZKsZQXjGcaM5GiypM8AWS5ihmHCpkQsQSpiwpQggIluQad5HGfXOxjV437XqMP5cKtG9s1lpwJmebdXjsq2lPGB9yWq8bU0LQlNF-lzOIsLUcfn6WYDLod35_Lt_gXmrdxzw</recordid><startdate>200204</startdate><enddate>200204</enddate><creator>Sanjuliani, A.F.</creator><creator>Genelhu-Fagundes, V.</creator><creator>Barroso, S.G.</creator><creator>Duarte, A.V.B.</creator><creator>Rodrigues, M.L.G.</creator><creator>Castro, R.S.P.</creator><creator>Lau, C.S.C.</creator><creator>Francischetti, E.A.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>200204</creationdate><title>P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients</title><author>Sanjuliani, A.F. ; Genelhu-Fagundes, V. ; Barroso, S.G. ; Duarte, A.V.B. ; Rodrigues, M.L.G. ; Castro, R.S.P. ; Lau, C.S.C. ; Francischetti, E.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i668-ca6ea6eebcc0519017fe725ec8484ae08c301abe02236a6f9bae6acac61faf483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Insulin Resistance</topic><topic>Moxonidine</topic><topic>Sympathetic Activity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Genelhu-Fagundes, V.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Duarte, A.V.B.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Castro, R.S.P.</creatorcontrib><creatorcontrib>Lau, C.S.C.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanjuliani, A.F.</au><au>Genelhu-Fagundes, V.</au><au>Barroso, S.G.</au><au>Duarte, A.V.B.</au><au>Rodrigues, M.L.G.</au><au>Castro, R.S.P.</au><au>Lau, C.S.C.</au><au>Francischetti, E.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2002-04</date><risdate>2002</risdate><volume>15</volume><issue>S3</issue><spage>51A</spage><epage>52A</epage><pages>51A-52A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract><![CDATA[The objective of the present study was to evaluate the effects of an imidazoline agonist, Moxonidine, on sympathetic nervous activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. Forty obese hypertensive, non diabetic patients were randomized to receive during 6 months Moxonidine (M), 0.2mg/day adjusted to 0.4 mg/day [3 males, 16 females, age = 50.3±1.9 yrs, BMI=35.4±1.7, mean blood pressure (MBP)=128±1.3 mmHg] or Amlodipine (AM) 5mg adjusted to 10 mg/day (4 males, 17 females, age 46.9±2.1 yrs, BMI = 35.9±1.4; MBP 122.7±1.7 mmHg). We evaluated the sympathetic activity by determination of arterial and venous cathecolamines (the last at supine and post-exercise othostatic position), serum insulin (fasting and 2h post oral glucose challenge), fasting leptin, lipid profile and anthropometrical variables. All these variables were measured before (V1), after 3 months (V2) and 6 months (V3) of treatment with both agents. Analysis of variance was used to evaluate the effects of both treatments. The following are results obtained at V1 and V3: A significant reduction on levels of blood pressure was achieved equally in both groups (MBP: 121.8±1.3 vs 107.1±2.0 mmHg for M and 158.1±3.1 vs 134.2±1.7 mmHg for A; all p<0.0001). Arterial nor-epinephrine (art NE) concentrations decreased significantly on M group (233.6±13.2 vs 194.3± 14.4 pg/ml, p<0.05) but not on AM group (195.5±15.2 vs 188.7±16.3, p=ns). Leptin concentrations also decreased significantly in M group (25.1±3.1vs 22.6±2.9 ng/ml, p=0.03) and increased in AM group (33.4±3.6 vs 36.6±7.9 ng/ml). Although no significant differences were registered on fasting serum insulin, we observed a significant decrease on 120 min. of insulin concentrations in M group (139.5±33.0 vs 71.2±14.5 μU/ml, p<0.05 ) but not in AM group (94.4±19.3 vs 88.5±11.5μU/ml, p=ns). The changes on art NE were directly associated to changes on 2h insulin (r=0.53, p<0.04) serum triglycerides (r=0.63, p<0.03) only in M group. The changes on serum leptin were also directly associated to 2h insulin (r=0.58, p<0.04) in M group. The beneficial effect achieved by Moxonidine goes beyond blood pressure control as result of a better metabolic profile associated with lower sympathetic activity.]]></abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/S0895-7061(02)02403-2</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-7061 |
| ispartof | American journal of hypertension, 2002-04, Vol.15 (S3), p.51A-52A |
| issn | 0895-7061 1941-7225 |
| language | eng |
| recordid | cdi_proquest_journals_1026584038 |
| source | Alma/SFX Local Collection; Oxford Journals |
| subjects | Insulin Resistance Moxonidine Sympathetic Activity |
| title | P-52: Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A20%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P-52:%20Effects%20of%20moxonidine%20on%20sympathetic%20activity,%20and%20metabolic%20and%20hemodynamic%20variables%20in%20obese%20hypertensive%20patients&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Sanjuliani,%20A.F.&rft.date=2002-04&rft.volume=15&rft.issue=S3&rft.spage=51A&rft.epage=52A&rft.pages=51A-52A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/S0895-7061(02)02403-2&rft_dat=%3Cproquest_istex%3E2712863881%3C/proquest_istex%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026584038&rft_id=info:pmid/&rfr_iscdi=true |